IMMUNE RESPONSE an der Nasdaq mit 20% im Plus !!! (Weiß jemand wieso?) - 500 Beiträge pro Seite

[T-ONLINEPUSHER]

Haben die etwa den Durchbruch mit Ihrem Aidswirkstoff geschafft, oder womit kann man die Kaufwut der letzten zwei Tage erklären.

Wäre über eine Erklärung (soweit es eine gibt) sehr dankbar !!!

Grüsse,

TP

[Börsencrash]

Schau mal das an. Das wird wohl der Grund sein.


AIDS drugs work to an extent but a bolstered immune system is still a necessity. Remune would fit the spot and is the most tested. IMHO.

-----------------------------------
South Africa to press for cheaper AIDS drugs

JOHANNESBURG, Jun 05 (Reuters) - South Africa said on Monday it would lobby international drug companies to implement promised price cuts and provide technical assistance to help combat the AIDS epidemic.

Five of the world`s top drug firms last month agreed to cut the prices of treatments for HIV, the virus that causes AIDS, in an initiative brokered by the United Nations to make the costly drugs affordable for millions in poor nations in Africa.

Health Minister Manto Tshabalala-Msimang said a task team would meet the companies in about a month to press them to implement the price cuts for AIDS treatments and other medicines.

"If indeed they are thinking of reducing the cost of drugs, they must understand it is not just anti-retroviral, it is all drugs, but in particular to manage opportunistic infections," Tshabalala-Msimang told Reuters.

South Africa, where one in 10 of the country`s 43 million people are HIV-positive, has refused to make the anti-AIDS drug AZT available in public clinics on cost grounds.

President Thabo Mbeki has sparked controversy by allowing so-called "AIDS dissidents" who deny that HIV causes AIDS onto an influential presidential advisory committee.

The task team--which would represent African countries and be joined by UNAIDS, the UN body coordinating the fight against the disease, and the World Health Organisation--would also press for assistance in developing medical infrastructure.

"They should be willing to assist us in developing the infrastructure... particularly developing the capacities of our laboratories so that we would then be able to monitor the patients that are being treated," she added. Msimang said South Africa needed outside assistance as the cost of treating an AIDS patient was prohibitive.

"It costs 70,000 South African rand ($10,100) a year to treat one AIDS patient and I don`t have the budget with only two billion rand a year," she said.

Some 7.5 million South Africans are forecast to be infected with HIV by 2010.

[SCIQUEST]

Wir werden noch viel Spaß mit diesem Stock haben ;-) Wenn die erst mal eine Zulassung haben , was durchaus zu erwarten ist, (siehe Pipeline) dann, ja dann $$$,-
Habe übrigens überarbeitete Homepage,sieht nich mehr ganz so lasch aus, nur nebenbei...

[Jumago]

ja wird auch Zeit, das ATH bei $60 feiert nächstes Jahr
sein 10jähriges...

http://www.bigcharts.com/custom/ragingbull-com/chart.asp?sym…

[grama]

An der Nasdaq 12 % im MINUS !
Kennt jemand die Gründe ?

[MSolver]

keep cool,
da wollen halt einige ihre Gewinne mit ins Wochenende nehmen.

[gimmequote!]

hi,

bin immune-bulle, kann aber eins nicht leugnen, @msolver - die nehmen aber viel gewinn mit!

gimmequote!

[kdiekmann]

Ich bin nicht so gut in Englisch.Hier ist die Meldung


Friday June 9, 8:19 am Eastern Time
Enrollment in AIDS vaccine study is halted
NEW YORK, June 9 (Reuters) - The AIDS Clinical Trials Group (ACTG) has stopped enrolling new patients in a trial of the effectiveness and safety of the experimental AIDS vaccine REMUNE, Immune Response Corp. and Agouron Pharmaceuticals Inc. said on Friday.

ACTG is reviewing protocol changes; a revised protocol is expected to be developed quickly, the companies said. The study is designed to discover whether vaccine-induced immune responses could help control the HIV virus and whether the intervention could prolong the effectiveness of potent antiretroviral therapy.

The 131 participants already enrolled in the 96-week, randomized, double-blind, controlled study will continue to be followed under the current protocol until a new protocol can be developed, the companies said.

Immune Response (NasdaqNM:IMNR - news) makes the REMUNE vaccine. The company is collaborating with Agouron, a unit of Warner-Lambert Co. (NYSE:WLA - news), in the development and commercialization of the vaccine.

REMUNE is being studied in several other clinical trials in the United States and Europe, and one trial has been completed in Thailand. Additionally, the National Institutes of Health is sponsoring other trials of REMUNE in adults and children.